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Abstract: Low adherence to pharmacological treatment is often associated with poor blood 
pressure control, but identification of nonadherent patients in outpatient settings is difficult. The 
aim of the study was to translate and evaluate the psychometric properties of the Polish version 
of the structured self-report eight-item Morisky Medication Adherence Scale (MMAS-8) among 
patients with hypertension. The study was conducted in a family doctor practice between January 
and July 2015. After a standard “forward–backward” procedure to translate MMAS-8 into Polish, 
the questionnaire was administered to 160 patients with hypertension. Reliability was tested 
using a measure of internal consistency (Cronbach’s α) and test–retest reliability. Validity was 
confirmed using known group validity. Three levels of adherence were considered based on 
the following scores: 0 to ,6 (low); 6 to ,8 (medium); and 8 (high). Complete questionnaires 
were returned by 110 respondents (mean age: 60.7 years ±12.6; 54.6% were female). The mean 
number of pills taken daily was 3.61±4.31. The mean adherence score was 6.42± 2.0. Moderate 
internal consistency was found (Cronbach’s α=0.81), and test–retest reliability was satisfactory 
(r=0.461–0.905; P,0.001). Reproducibility expressed by Cohen’s κ coefficient =0.61 was 
good. In high-adherent patients, the percentage of well-controlled blood pressure was higher 
than in low-adherent patients (33.3% vs 19.1%, χ2=0.87, P=0.648). Psychometric evaluation 
of the Polish version of the MMAS-8 indicates that it is a reliable and valid measure tool to 
detect nonadherent patients. The MMAS-8 may be routinely used to support communication 
about the medication-taking behavior in hypertensive patients.
Keywords: Morisky scale, medication adherence, hypertension, validation, pharmacological 
treatment
Introduction
Hypertension is one of the most commonly spread risk factors for cardiovascular 
diseases. The World Health Organization has estimated that one in eight deaths are 
caused by hypertension; thus, hypertension is considered the third-most common 
cause of mortality worldwide.1 The prevalence of hypertension among adults ranges 
from 10% to 20% and among people over 50 years of age increases up to 40%–50%. 
The prevalence of hypertension in European countries is about 60% higher than in the 
USA or Canada.2 In Poland, hypertension is diagnosed in 29% of adult population, 
and only 12% of patients are treated properly.3
Effective treatment of hypertension is based on lifestyle modification and long-
term pharmacotherapy; however, about 40%–60% of patients with hypertension fail 
to comply with the prescribed treatment4 and about 50% stop taking their drugs during 
the first 12 months of treatment and 30% do not take them as prescribed.5 Poor blood 
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pressure control is often associated with nonadherence, but 
on the other hand, poor adherence occurs more often in 
primary prevention and in asymptomatic patients.4
Adherence to antihypertensive medication is a key deter-
minant of adequate blood pressure control and prevention of 
cardiovascular events,6 but studies from the literature show 
that the recognition of noncompliant patients by health care 
providers is low (10%–38%). The lack of blood pressure 
control may serve as an alarming sign of nonadherence.7 
Assessment of health records and evaluation of patients’ 
expectations for the treatment may help in identifying non-
adherent patients. Also, the important role of questionnaires 
in the assessment of adherence to therapeutic recommenda-
tions is emphasized.8
To date, no universal method for the measurement 
of medication adherence exists, although several scales 
specific for adherence measurement based on patient’s 
self-assessment are available. Apart from adherence, they 
often aim at identification of inconvenience related to taking 
drugs, attitudes and beliefs about treatment, or the level of 
knowledge about the disease and its treatment. None of the 
scales are available in the Polish language.9
The most commonly used adherence-specific self-report 
questionnaire is the Morisky Medication Adherence Scale 
(MMAS).10–12 This scale was originally established as a 
four-item questionnaire in patients with hypertension. It 
has been expanded with four additional items that address 
the circumstances regarding adherence behavior. This new 
version is called the eight-item MMAS (MMAS-8). The 
ranging score is from 0 to 8, with higher scores indicat-
ing better adherence. The MMAS-8 has been adapted and 
validated in many languages and for a variety of chronic 
diseases that require customized assessment of the recom-
mendations.10 Therefore, we adapted it to the Polish culture 
and carried out its validation in a group of patients with 
hypertension.
Aim
In the present study, we report the results of the validation 
study.
Methods
Patients and study design
The study protocol and informed consent form was 
approved by the independent Commission of Bioethics 
at Wroclaw Medical University (consent number KB 
136/2015). For the study, patients attending the family 
doctor practice in Wroclaw between January and July 2015 
were enrolled.
inclusion criteria
To be included in the study, patients had to:
1. be diagnosed with hypertension at least 1 year before, 
which is in accordance with the guidelines of the 
European Society of Hypertension,
2. be treated with antihypertensive medication (at least one 
drug),
3. be older than 18 years,
4. sign an informed consent, and
5. be able to read Polish.
exclusion criteria
The patients excluded from the study:
1. had limited cognitive functions,
2. did not sign an informed consent, and
3. were diagnosed with any other serious disease (neoplasm, 
cardiac and renal insufficiency, etc).
Two tests were planned in the study at an interval of 
4 weeks. At admission, nurses asked the patients to complete 
the questionnaire. One month after admission, the question-
naire was sent to each patient’s home and they were asked 
to complete it again.
All respondents gave written informed consent for par-
ticipation in the study. We decided that the best method for 
standardizing our sample size data was subject to item ratio 
because we needed a criterion for a reasonable direct compari-
son to our own data analysis. This corresponds to 20 patients 
for an eight-item questionnaire.13 With this sample size, the 
width of the 95% confidence interval for a Cronbach’s α coef-
ficient of 0.80 is 0.05. We decided to include 160 patients.
MMAs questionnaire
The MMAS-8 is a self-report questionnaire with eight 
questions. Self-reported medication adherence was assessed 
using the MMAS-8. The self-reported MMAS-8 tool is simple 
to administer and is a reliable and an economical method in 
clinical practice. The MMAS-8 was designed to facilitate the 
identification of barriers to and behaviors associated with adher-
ence to chronic medication. The tool has been determined to be 
reliable and significantly associated with blood pressure control 
in individuals with hypertension, as well as with antihyperten-
sive medication pharmacy fill rates. Scores on the MMAS-8 
range from 0 to 8, with scores of ,6 reflecting low, 6 to ,8 
reflecting medium, and 8 reflecting high adherence.10,14–16
Translation and cross-cultural adaptation 
of the MMAs-8
The eight items of the MMAS were translated by the Mapi 
Research Institute according to international guidelines:17,18
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1. Two independent Polish translations were obtained from 
two independent translators. The Polish version was 
prepared during a meeting attended by a multidisciplinary 
team consisting of two physicians, two nurses, and two 
pharmacists.
2. The reverse translation from Polish to English was car-
ried out by another translator who was not involved in 
developing the initial version.
3. The original and the back-translated English versions 
were compared and the problems with inconsistencies 
resolved in another meeting.
A pilot study was performed in a Polish population of 
25 patients. The patients who participated in this face-validity 
phase were not included further in the study. The final ver-
sion of the questionnaire was approved by the author of the 
original version, and then it was completed and made avail-
able for the reliability and validity study.
statistical analysis
Statistical analysis of the obtained results was carried out 
with the Statistica software v.10 (StatSoft, Tulsa, OK, 
USA). Normality of analyzed variables was verified by 
the Kolmogorov–Smirnov test. Statistical characteristics 
of variables are presented as arithmetical mean ± standard 
deviation (SD), median, and interquartile range. Statistical 
characteristics of discrete and qualitative variables are pre-
sented as frequency distribution (n). Internal consistency and 
intraclass correlation coefficients of the Polish adaptation of 
the questionnaire were tested by Cronbach’s α coefficient. 
Exploratory factor analysis was used to identify relationships 
between questionnaire items. Test–retest reliability was 
assessed at a 4-week interval to evaluate reproducibility of 
the Polish version of the questionnaire.
Results
clinical and demographic data
For the study, 160 patients with hypertension who met the 
inclusion criteria were enrolled. The first study was com-
pleted by all of the patients who agreed to participate, while 
in the repeat study, 43 patients withdrew (26.8% refusal 
rate) and seven returned incomplete questionnaires. The 
second questionnaire was sent to all the 160 respondents by 
post, and 43 of them did not send it back. The final analysis 
included 110 patients with hypertension. The characteristics 
of the total and adherent groups are shown in Table 1. Of 
the 110 patients, 27 (24.5%), 43 (39.1%), and 40 (36.4%) 
were in the low-, medium-, and high-adherence groups, 
respectively. Significant differences in blood pressure control 
were found in patients with high adherence who took their 
medications once or twice a day compared to patients with 
low adherence who took their medications only when they 
feel symptoms.
The mean age of respondents was 60.7 years of age 
(SD, 12.6). Patients in the group with high adherence 
were older than patients in the group with low adherence 
(62.9 years, SD 11.0 vs 58.1 years, SD 13.0); however, the dif-
ference between those groups was not significant. Of the study 
group, 54.6% were women; the percentage of women was 
higher in the group with high adherence than in the group 
with low adherence (60% vs 51.8%; not significant). Half of 
the respondents had been educated to a secondary education 
level. The majority of respondents from the three groups 
were married or in a relationship (63% vs 76.7% vs 60%, 
respectively). The mean time from diagnosis of hypertension 
was 9.2 years (SD, 7.4) and was the shortest in the group of 
patients with high adherence (8.4 years; SD, 4.7). Patients 
were taking 3.61 (SD, 4.31) antihypertensive tablets a day. 
Detailed characteristics are presented in Table 1.
Table 2 presents the analysis of adherence levels of 
MMAS on the group of patients with hypertension. Mean 
level of adherence according to MMAS-8 was 6.42 (SD, 
2.00), which indicates medium adherence to pharmacologi-
cal recommendation.
construct validity of the scale
Two factors were included in the analysis based on the 
number of plotted points before the last drop. In this way, 
eight input variables were reduced to two dimensions that 
explained 59.9% of the total variance. Factor loading table 
shows that the most important common factor (Factor 1) 
is associated mostly with variables describing patients’ 
behavior in the past, while the second one (Factor 2) is 
associated with taking medicines the day before complet-
ing the questionnaire. Factor loadings are presented in 
Table 3.
reliability of the scale
The Polish version of MMAS-8 adherence scale is a reli-
able method of verifying medication adherence. The overall 
Cronbach’s α coefficient was 0.808, and the mean correlation 
among items of the scale was 0.361. Table 4 presents basic 
characteristics of respective items of the scale and their con-
tribution to the whole adherence scale. This table shows that 
not all items influence the reliability of the scale to a similar 
extent. The strongest correlation appears between the entire 
scale and item number 6; thus, the decrease in reliability 
would also be the strongest, if this was removed from the 
scale. The weakest influence on the reliability appears in 
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case of item 5. If item 5 were removed from the scale, the 
mean correlation between items of the scale would increase 
to 0.476. The remaining items would have similar contribu-
tion to the reliability, and the reliability coefficient would 
increase to 0.85.
Known group validity
In the group with high adherence, the percentage of patients 
with properly controlled blood pressure was higher than in 
the group with low adherence (33.3% vs 19.1%, P.0.05). 
Also, mean systolic and diastolic blood pressure were lower 
in the high-adherent group than in the low-adherent one 
(141 vs 145 and 84 vs 90 mmHg, respectively). Both dif-
ferences were statistically insignificant (P.0.05). Table 4 
shows distribution of levels of adherence in relation to proper 
blood pressure control.
Test–retest reliability
A total of 110 questionnaires were returned 1 month after 
admission and assessed by test–retest method. The results 
Table 1 characteristics of patients according to the groups of adherence
Characteristic Total (n=110) Low (n=27) Medium (n=43) High (n=40) F/χ2 P-value
Age (y), n (sD) 60.7 (12.6) 58.1 (13.0) 60.2 (13.6) 62.9 (11.0) 1.231 0.296
BMi (kg/m2), n (sD) 27.8 (4.4) 28.9 (4.5) 27.6 (4.5) 27.3 (4.0) 1.081 0.343
Female 60 (54.6%) 14 (51.8%) 22 (51.2%) 24 (60.0%) 0.757 0.685
education level 5.271 0.261
Primary and below 31 (28.2%) 5 (18.5%) 16 (37.2%) 10 (25.0%)
secondary school 55 (50.0%) 17 (63.0%) 16 (37.2%) 22 (55.0%)
college and above 24 (21.8%) 5 (18.5%) 11 (25.6%) 8 (20.0%)
Marital status 3.115 0.374
Marriage and partnership 74 (67.3%) 17 (63.0%) 33 (76.7%) 24 (60.0%)
Divorcee/single 15 (13.7%) 5 (18.5%) 4 (9.3%) 6 (15.0%)
Widow/widower 21 (19.1%) 5 (18.5%) 6 (14.0%) 10 (25.0%)
employment status 4.744 0.577
Working 48 (43.6%) 12 (44.4%) 20 (46.5%) 16 (40.0%)
retired 51 (46.4%) 11 (40.8%) 18 (41.9%) 22 (55.0%)
Pensioned 8 (7.3%) 3 (11.1%) 3 (7.0%) 2 (5.0%)
Unemployed 3 (2.7%) 1 (3.7%) 2 (4.6%) 0 (0.0%)
Time from hBP diagnosis 9.5 (7.5) 9.3 (6.3) 10.9 (8.4) 8.2 (7.0) 1.343 0.265
Classification of hypertension 9.283 0.158
normal 3 (2.7%) 0 (0.0%) 0 (0.0%) 3 (7.5%)
high-normal 18 (16.4%) 4 (14.8%) 10 (23.3%) 4 (10.0%)
grade 1 (mild) 59 (53.6%) 16 (59.3%) 20 (46.5%) 23 (57.5%)
grade 2 (moderate) 30 (27.3%) 7 (25.9%) 13 (30.2%) 10 (25.0%)
nicotine addiction 7.183 0.127
never smoked 60 (55.0%) 12 (44.4%) 23 (53.5%) 25 (64.1%)
no longer smoker 20 (18.4%) 3 (11.2%) 9 (20.9%) 8 (20.5%)
current smoker 29 (26.6%) 12 (44.4%) 11 (25.6%) 6 (15.4%)
Alcohol 6.636 0.465
At all 37 (33.6%) 7 (25.9%) 13 (30.2%) 17 (42.5%)
sometimes 65 (59.1%) 17 (63.0%) 26 (60.5%) 22 (55.0%)
Often 7 (6.4%) 3 (11.1%) 3 (7.0%) 1 (2.5%)
Daily 1 (0.9%) 0 (0.0%) 1 (2.3%) 0 (0.0%)
Frequency of BP control 33.46 0.001
Three times a day 9 (8.2%) 2 (7.4%) 3 (7.0%) 4 (10.0%)
Twice a day 32 (29.1%) 7 (25.9%) 10 (23.3%) 15 (37.5%)
Once a day 34 (30.9%) 5 (18.5%) 13 (30.2%) 16 (40.0%)
Once a week 14 (12.7%) 1 (3.7%) 10 (23.3%) 3 (7.5%)
Only a doctor 8 (7.3%) 3 (11.1%) 5 (11.6%) 0 (0.0%)
When ill feeling 13 (11.8%) 9 (33.3%) 2 (4.6%) 2 (5.0%)
Frequency of medication 5.664 0.226
More often than once a day 36 (32.7%) 10 (37.0%) 17 (39.5%) 9 (22.5%)
Once a day 66 (60.0%) 14 (51.9%) 25 (58.1%) 27 (67.5%)
number of medications daily 3.61 (4.31) 5.42 (3.64) 4.75 (3.18) 2.64 (3.18) 7.862 0.062
Note: Statistical significance marked in bold.
Abbreviations: BP, blood pressure; hBP, high blood pressure; BMi, body mass index.
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are presented in Table 5 as number of answers, Cohen’s κ 
coefficient, Spearman’s rank correlation coefficient, and 
consistency. Correlations between the same items are 
statistically significant at a level of P,0.001, though not 
equally strong (from ρ=0.461 to 0.905); the strongest cor-
relation occurred for question 4 (Q4) and the weakest was 
for question 5 (Q5). The analysis of results obtained during 
double test among the same people revealed good reproduc-
ibility (Cohen’s κ coefficient =0.61). The overall results are 
presented in Table 6.
Discussion
The main objective of this paper was to evaluate the reliability 
and validity of the translated version of the MMAS-8 in a 
sample of patients with hypertension. This study was the first 
to systematically translate and validate the MMAS-8 into 
the Polish language. To date, the MMAS-8 questionnaire 
has been translated into several languages and used among 
patients with hypertension and diabetes.11,17,19–23
The evaluation of nonadherence to pharmacological 
recommendations is necessary in clinical practice, but it still 
Table 2 Analysis of adherence levels of MMAs depending on the degree of illness acceptance
Morisky Medication Adherence Scale Moderate illness acceptance (19–29 points)
Do you sometimes forget to take your pills? 0.66±0.47
People sometimes miss taking their medications for reasons other than forgetting. Thinking  
back over the past 2 weeks, were there any days when you did not take your medicine?
0.81±0.39
have you every cut back on or stopped taking your medication without telling your doctor,  
because you felt worse when you took it?
0.83±0.38
When you travel or leave home, do you sometimes forget to take your medication with you? 0.74±0.44
Did you take your medicine yesterday? 0.87±0.33
When you feel like your illness is under control, do you sometimes stop taking your medicine? 0.84±0.37
Taking medication every day is a real inconvenience for some people. Do you ever feel hassled  
about sticking to your treatment plan?
0.80±0.40
How often do you have difficulty remembering to take all your medications? 0.88±0.21
never/rarely (4)
Once in a while (3)
sometime (2)
Usually (1)
All the time (0)
MMAs-8-Total 6.42±2.00
Adherence level, n (%)
low adherence (,6) 27 (24.5)
Medium adherence (6–8) 43 (39.1)
high adherence (=8) 40 (36.4)
Notes: Use of the ©MMAs-8 is protected by the Us copyright laws. Permission for use is required. A licensure agreement is available from Donald e Morisky, scD, 
scM, MsPh, Professor, Department of community health sciences, UclA school of Public health, 650 charles e Young Drive south, los Angeles, cA 90095-1772; 
dmorisky@gmail.com. Data shown as mean ± sD unless stated otherwise.
Abbreviation: MMAs-8, eight-item Morisky Medication Adherence scale.
Table 3 corrected item-to-total correlation and factors loading of the Polish MMAs-8
Items Patients’ 
responses
Entry (n=110), 
number (%)
Corrected item-to-
total correlation
α if 
deleted
Factor
Factor 1 Factor 2
Q1 no 73 (66.4) 0.589 0.777 0.719 0.032
Q2 no 89 (80.9) 0.565 0.780 0.700 -0.218
Q3 no 91 (82.7) 0.524 0.786 0.670 -0.198
Q4 no 81 (73.6) 0.661 0.763 0.784 0.010
Q5 Yes 96 (87.3) 0.031 0.849 0.055 0.955
Q6 no 92 (83.6) 0.686 0.762 0.800 -0.003
Q7 no 88 (80.0) 0.635 0.769 0.741 0.090
Q8 never/rarely 3 (2.7) 0.580 0.791 0.692 0.199
Once in a while 10 (9.1)
sometimes 20 (18.2)
Usually 76 (69.1)
All the time 1 (0.9)
Note: Statistically significant values are shown in bold.
Abbreviations: n, sample size; MMAs-8, eight-item Morisky Medication Adherence scale; α, Cronbach’s alpha coefficient.
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Table 5 Test–retest result
Questions (items) Test 1 Test 2 κ ρ
No Yes C (%)
Q1  Do you sometimes forget to take your antihypertensive pills? no 72 5 0.874 0.878
Yes 1 32 94.5%
Q2  People sometimes miss taking their medications for reasons other 
than forgetting. Thinking over the past 2 weeks, were there any 
days when you did not take your antihypertensive medicine?
no 88 7 0.751 0.751
Yes 1 14 92.7%
Q3  have you ever cut back or stopped taking your medication 
without telling your doctor, because you felt worse when you 
took it?
no 87 1 0.850 0.854
Yes 4 18 95.5%
Q4  When you travel or leave home, do you sometimes forget to 
bring along your antihypertensive medicine?
no 80 3 0.904 0.905
Yes 1 26 95.5%
Q5  Did you take your antihypertensive medicine yesterday? no 8 8 0.460 0.461
Yes 6 88 12.7%
Q6  When you feel like your hypertension is under control, do you 
sometimes stop taking your medicine?
no 90 2 0.867 0.867
Yes 2 16 96.4%
Q7  Taking medication every day is a real inconvenience for some 
people. Do you ever feel hassled about sticking to your 
antihypertensive treatment plan?
no 86 5 0.790 0.794
Yes 2 17 93.6%
Test 1 Test 2
a) b) c) d) e)
Q8  How often do you have difficulty remembering to take all your 
medications?
 never/rarely a) 75 1 1 1 1 0.727 0.854
 Once in a while b) 0 15 1 0 0
 sometimes c) 1 4 8 0 0 90.1%
 Usually d) 0 0 0 2 0
 All the time e) 0 0 0 0 0
Abbreviations: κ, Cohen’s kappa coefficient; ρ, Spearman’s rank correlation coefficient; C, consistency.
Table 4 relations between level of adherence and blood pressure control groups
Adherence level 
(MMAS-8)
Blood pressure Mean (SD)
Control Blood pressure values
Yes, n (%) No, n (%) SBP, mmHg DBP, mmHg
low adherence (,6) 4 (19.1) 23 (25.8) 145 (17) 90 (8)
Medium adherence (6 to ,8) 10 (47.6) 33 (37.1) 147 (14) 91 (12)
high adherence (8) 7 (33.3) 33 (37.1) 141 (11) 84 (12)
Abbreviations: sBP, systolic blood pressure; DBP, diastolic blood pressure; sD, standard deviation; MMAs-8, eight-item Morisky Medication Adherence scale.
remains difficult. Patient self-assessment related to adherence 
to prescribed medication seems to be a simple and inexpen-
sive method of obtaining information, as long as properly 
prepared examination tools are available in daily clinical 
practice. One of the measures of adherence is the percentage 
of the medication actually taken by the patient. It must be 
assumed that the omission of more than 80% of prescribed 
doses of medication means total nonadherence, while omis-
sion of less than 20% means partial cooperation. A high 
percentage of patients admit that they do not take medication 
daily for various reasons and, moreover, they are not able to 
accurately calculate the number of omitted doses.7
Among the indirect methods of verifying adherence to 
medication, the following procedures are used the most 
often: direct observation of treatment process, electronic 
monitoring systems registering the time of opening canisters 
with drugs, monitoring of drug concentration in physiologi-
cal fluids, and patient’s response to applied medication with 
the use of physiological markers such as heart rate. These 
methods, however, are imprecise and too costly. One of the 
best assessment methods of the level of adherence is direct 
interview with a patient including questions about the type 
of drugs, their doses, and the number of daily doses. Patients 
without impaired cognitive function and those who cooper-
ate well are able to give correct answers or use a prepared 
written instruction.
Identification of factors affecting the level of adherence 
among patients with hypertension is a crucial element in 
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Table 6 Frequency table and χ2 test
Test 2
Adherence 
level
Test 1
Adherence level
Percentage 
(%)
Low Medium High
low 26 2 1 26.4
Medium 1 29 4 30.9
high 0 12 35 42.7
24.5% 39.1% 36.4%
Notes: χ2=129.6, df =4, P,0.0001, κ=0.606.
Abbreviations: df, degrees of freedom; κ, Cohen’s kappa coefficient.
improving patients’ compliance to following therapeutic 
recommendations. Based on the available studies, a profile of 
patients with increased risk for nonadherence can be estab-
lished. This group includes young men with comorbidities and 
low socioeconomic status. In addition, it was proved that non-
working, smoking patients with low social support and reduced 
satisfaction with their medication because of the presence of 
side effects of the treatment have significantly greater amount 
of problems with adherence to medication regimens.21
The original MMAS-8 scale was tested by Morisky 
et al10 on a sample of hypertensive patients, and it was found 
that the scale was reliable with good predictive validity 
and sensitivity (Cronbach’s α=0.83) and was significantly 
associated with blood pressure control (P,0.05). Other stud-
ies evaluated the MMAS-8 translated version in Brazilian 
Portuguese, Thai, French, Malaysian, Korean, Persian, and 
Chinese.11,19–21,23–25 These studies show that the MMAS-8 
translated version had acceptable internal consistency, good 
test–retest reliability, and good convergent validity. The 
questionnaire was primarily dedicated to measure adherence 
among patients with hypertension; however, currently, it is 
also often used among diabetic and cardiac patients as well 
as in patients with asthma, psoriasis and AIDS.20,22,24,26
The MMAS-8 questionnaire was translated into several 
languages. The level of internal consistency of Polish adap-
tation of MMAS-8 was α=0.81, and the mean correlation 
between items of the scale was 0.36. The values are similar to 
those obtained for the original version of the questionnaire.10 
The psychometric properties of the foreign versions were rec-
ognized as satisfactory, although their parameters of internal 
consistency were lower than those for the Polish version. The 
Cronbach’s α was 0.682 for the Brazilian Portuguese version, 
0.54 for the French version, 0.697 for the Persian version, 
while it was 0.808 for the Polish version.11,12,21
Our study among Polish patients with hypertension 
showed that the MMAS-8 had good test–retest reliability 
(r=0.61) with good convergent validity and sensitivity 
(59.9%). In terms of internal consistency and test–retest 
reliability, it is different from the results of de Oliveira-
Filho et al11 and Moharamzad et al12. These authors, 
however, performed the reproducibility assessment after 
2 weeks, which showed that the ability to change adher-
ence to pharmacological recommendations is less possible 
in such a short period of time – in the present study, the 
interval between questionnaires was 4 weeks. The Polish 
version of MMAS-8 questionnaire was able to differenti-
ate significantly between patients with well-controlled and 
uncontrolled blood pressure. In the present study, patients 
with well-controlled blood pressure obtained higher score 
in MMAS-8 questionnaire, showing better adherence than 
those with uncontrolled blood pressure. Significant correla-
tion between MMAS-8 questionnaire and the level of blood 
pressure control was confirmed in the study on the original 
version of the questionnaire and in the studies of other 
researchers.10,11
Conclusion
Identification of nonadherent patients is important to improve 
the effectiveness of antihypertensive treatment. The Polish 
version of MMAS-8 questionnaire is a reliable and valid 
measure of medication adherence in hypertensive patients. 
This questionnaire should be used in daily clinical practice, 
especially in patients with uncontrolled hypertension despite 
correctly applied therapeutic regimens. Recognition of non-
adherent patients along with finding reasons for their lack of 
adherence may allow for the development of strategies for 
improving adherence. The Polish version of the questionnaire 
may be used in routine care to support communication about 
the medication-taking behavior.
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